Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.34 |
| ▸ | Q9HBH1 | 1/20 | 0.33 | |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 7/20 | 0.31 |
| ▸ | MMP3 | P08254 | 6/20 | 0.31 |
| ▸ | MMP9 | P14780 | 6/20 | 0.31 |
| ▸ | MMP2 | P08253 | 6/20 | 0.31 |
| ▸ | MMP8 | P22894 | 4/20 | 0.31 |
| ▸ | MMP13 | P45452 | 3/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 2/20 | 0.30 |
| ▸ | MMP14 | P50281 | 2/20 | 0.30 |
| ▸ | MMP20 | O60882 | 1/20 | 0.30 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | MMP10 | P09238 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP15 | P51511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706304 | 1.00 | HIF1A (0.34) | HIF1AADAM17PDFCA1CA2 | |
| Hydrochloric Acid SCHEMBL2286815 | 0.98 | HIF1A (0.33) | HIF1AADAM17PDFCA1CA2 | |
| SCHEMBL1213869 | 0.85 | CA2 (0.46) | CA1CA2CA7 | |
| SCHEMBL21012805 | 0.83 | HIF1A (0.31) | HIF1ACA1CA2 | |
| Hydrochloric Acid SCHEMBL30205399 | 0.82 | HIF1A (0.30) | HIF1A | |
| SCHEMBL13051146 | 0.82 | ADAM17 (0.48) | ADAM17MMP1MMP3MMP9MMP2 | |
| SCHEMBL4676064 | 0.79 | HIF1A (0.37) | HIF1AADAM17PDFCA1CA2 | |
| SCHEMBL3556829 | 0.79 | HIF1A (0.37) | HIF1AADAM17PDFCA1CA2 | |
| SCHEMBL10204084 | 0.79 | CNR2 (0.35) | CA1CA2MMP9CA7 | |
| SCHEMBL7765969 | 0.79 | CNR2 (0.35) | CA1CA2MMP9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12084455-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-3909949-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11078208-B1 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-10806794-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2020-10-20 | — | — | US | disclosed |
| EP-1851193-A1 | HIV PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007048557-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2006084688-A1 | HIV protease inhibitors | MEDIVIR AB (SE) | 2006-08-17 | — | — | WO | disclosed |
| EP-0900210-B1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6300519-B1 | REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND | NOVARTIS FINANCE CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6166004-A | Combinations of HIV protease inhibitors with reverse transcriptase inhibitors | NOVARTIS FINANCE CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885ADAM17 307/4885PDF 3663/4885 |
| US-10806794-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | HIF1A 2112/4885ADAM17 40/4885PDF 1820/4885 |
| US-11078208-B1 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885ADAM17 307/4885PDF 3663/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885ADAM17 307/4885PDF 3663/4885 |
| US-12084455-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885ADAM17 307/4885PDF 3663/4885 |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885ADAM17 307/4885PDF 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.